825600-90-6|Lucinactant|L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine, acetate|-范德生物科技公司

Lucinactant

NMR下载 COA and HPLC MSDS下载
names：
L-Lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-leucyl-L-lysine, acetate
CAS号：
825600-90-6
MDL Number：
MF(分子式)： C128H242N26O24 MW(分子量)： 2529.45
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Lucinactant
英文别名	Surfaxin
CAS号	825600-90-6
SMILES	NCCCC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O
Inchi
InchiKey	OSPNFKYGOFXGBX-YWWKUQGPSA-N
分子式 Formula	C128H242N26O24
分子量 Molecular Weight	2529.45
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Lucinactant(CAS:825600-90-6):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Lucinactant (trade name Surfaxin) is a liquid medication used to treat Infant Respiratory Distress Syndrome in infants.[1] It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on March 6, 2012. (Source http//en.wikipedia.org/wiki/Lucinactant)
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Jordan BK, Donn SM. Lucinactant for the prevention of respiratory distress syndrome in premature infants. Expert Rev Clin Pharmacol. 2013 Mar;6(2):115-2[1]doi: 10.1586/ecp.12.80. Review. PubMed PMID: 23473590.

[2]Piehl E, Fernandez-Bustamante A. Lucinactant for the treatment of respiratory distress syndrome in neonates. Drugs Today (Barc). 2012 Sep;48(9):587-93. doi: 10.1358/dot.2012.48.9.1835160. Review. PubMed PMID: 23032799.

[3] Donn SM, Sinha SK. Aerosolized lucinactant: a potential alternative to intratracheal surfactant replacement therapy. Expert Opin Pharmacother. 2008 Feb;9(3):475-8. doi: 10.1517/14656566.9.3.475 . Review. PubMed PMID: 18220497.

[4] Donn SM. Lucinactant: a novel synthetic surfactant for the treatment of respiratory distress syndrome. Expert Opin Investig Drugs. 2005 Mar;14(3):329-34. Review. PubMed PMID: 15833063.

[5] Moen MD, Perry CM, Wellington K. Lucinactant: in neonatal respiratory distress syndrome. Treat Respir Med. 2005;4(2):139-45; discussion 146-7. Review. PubMed PMID: 15813666.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开